These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 25976428

  • 1. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI).
    Tseng YH, Hung HY, Sung YC, Tseng YC, Lee YC, Whang-Peng J, Chen YM.
    J Chemother; 2016; 28(1):50-8. PubMed ID: 25976428
    [Abstract] [Full Text] [Related]

  • 2. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
    Tseng YH, Tseng YC, Lin YH, Lee YC, Perng RP, Whang-Peng J, Chen YM.
    Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
    [Abstract] [Full Text] [Related]

  • 3. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 4. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
    Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L, Yang CH, Mok T.
    J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP.
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
    Koyama N, Uchida Y.
    Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
    [Abstract] [Full Text] [Related]

  • 14. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N.
    BMC Cancer; 2018 Jan 02; 18(1):6. PubMed ID: 29291705
    [Abstract] [Full Text] [Related]

  • 15. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C, An C, Feng Q, Ma Y, Li S, Wang J, Zhang J, Wang X, Yan S, Fang J, Wang Y, Tan F, Yang Y.
    Clin Lung Cancer; 2015 Nov 02; 16(6):e173-81. PubMed ID: 25958850
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
    Koo DH, Kim KP, Choi CM, Lee DH, Lee JC, Lee JS, Jang SJ, Kim SW.
    Cancer Chemother Pharmacol; 2015 Jan 02; 75(1):197-206. PubMed ID: 25422153
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group.
    J Thorac Oncol; 2010 Jan 02; 5(1):99-104. PubMed ID: 19898258
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.